Pharmaceuticals: Major
Major Austrian companies producing pharmaceuticals
Global pharmaceutical corporations develop and distribute prescription medications at a massive scale. Patent expirations, pipeline approvals, and healthcare legislation serve as major catalysts for trading activity and industry liquidity. Market data indicates that Novo Nordisk A/S Class B is currently the highest-volume asset, while Heidelberg Pharma AG tops the 24-hour return list. The table below tracks the vital technical and fundamental metrics for these equities.
Symbol | Mkt cap | Price | Chg % | Vol | Rel vol | P/E | EPS dil TTM | EPS dil growth TTM YoY | Div yield % TTM | Sector | Analyst rating |
|---|---|---|---|---|---|---|---|---|---|---|---|
 LLYCEli Lilly and Company | 1.19 T EUR | 1,222.4 EUR | −2.71% | 0 | 0.00 | 45.49 | 26.87 EUR | +55.94% | 0.47% | Health technology | Strong buy |
 JNJJohnson & Johnson | 592.45 B EUR | 244.80 EUR | −0.59% | 5 | 0.12 | 42.07 | 5.82 EUR | −34.10% | 1.91% | Health technology | Buy |
 ABBVAbbVie, Inc. | 464.16 B EUR | 259.6 EUR | −1.29% | 0 | 0.00 | 50.61 | 5.13 EUR | +354.14% | 2.35% | Health technology | Buy |
 ROGHRoche Holding Ltd | 343.88 B EUR | 427.0 EUR | −1.93% | 0 | 0.00 | 25.72 | 16.60 EUR | +32.10% | 2.69% | Health technology | Buy |
| ROGPRoche Holding Ltd | 343.88 B EUR | 419 EUR | −1.87% | 0 | 0.00 | 25.24 | 16.60 EUR | +32.10% | 2.48% | Health technology | Buy |
 MRKMerck & Co., Inc. | 330.4 B EUR | 131.62 EUR | −1.78% | 0 | 0.00 | 152.27 | 0.86 EUR | −86.58% | 2.26% | Health technology | Buy |
 NOVNNovartis AG | 267.8 B EUR | 143.02 EUR | −1.72% | 0 | 0.00 | 32.64 | 4.38 EUR | −33.91% | 2.76% | Health technology | Neutral |
 NNO2Novo Nordisk A/S Class B | 168.68 B EUR | 36.145 EUR | +0.25% | 2.9 K | 0.50 | 10.63 | 3.40 EUR | +9.26% | 4.10% | Health technology | Neutral |
 PFEPfizer Inc. | 156.31 B EUR | 26.315 EUR | −3.11% | 157 | 0.11 | 42.64 | 0.62 EUR | −57.78% | 5.59% | Health technology | Neutral |
 VRTXVertex Pharmaceuticals Incorporated | 123.98 B EUR | 489.90 EUR | +1.52% | 0 | 0.00 | 35.70 | 13.72 EUR | +13.49% | 0.00% | Health technology | Buy |
 BMYSBristol-Myers Squibb Company | 116.86 B EUR | 56.03 EUR | −1.67% | 0 | 0.00 | 14.06 | 3.98 EUR | +57.85% | 3.93% | Health technology | Buy |
 SANOSanofi SA | 100.88 B EUR | 80.98 EUR | −6.20% | 2 | 0.00 | 24.32 | 3.33 EUR | −35.60% | 4.90% | Health technology | Buy |
 REGNRegeneron Pharmaceuticals, Inc. | 85.73 B EUR | 807.3 EUR | −1.67% | 0 | 0.00 | 20.19 | 39.99 EUR | +12.33% | 0.40% | Health technology | Buy |
 MRCKMerck KGaA | 65.41 B EUR | 145.00 EUR | −4.98% | 0 | 0.00 | 26.60 | 5.45 EUR | −17.22% | 1.46% | Health technology | Buy |
 TKDTakeda Pharmaceutical Co. Ltd. | 59.1 B EUR | 37.42 EUR | −3.16% | 0 | — | 318.28 | 0.12 EUR | +2.11% | 3.07% | Health technology | Buy |
 UCBUCB S.A. | 53.69 B EUR | 282.4 EUR | −1.05% | 0 | 0.00 | 24.98 | 11.31 EUR | +64.98% | 0.36% | Health technology | Buy |
 BAYNBayer AG | 53.29 B EUR | 54.50 EUR | −3.16% | 967 | 0.29 | — | −1.77 EUR | +49.15% | 0.20% | Health technology | Buy |
 GALDGalderma Group AG | 49.43 B EUR | 210 EUR | −1.87% | 0 | 0.00 | 66.76 | 3.15 EUR | +113.32% | 0.18% | Health technology | Buy |
 SDZSandoz Group Ltd | 39.38 B EUR | 90.28 EUR | −0.62% | 0 | 0.00 | 70.79 | 1.28 EUR | +169.78% | 0.97% | Health technology | Neutral |
 BIIBBiogen Inc. | 33.5 B EUR | 222.00 EUR | −1.07% | 0 | 0.00 | 107.66 | 2.06 EUR | −77.93% | 0.00% | Health technology | Buy |
 ZOTSZoetis, Inc. Class A | 32.83 B EUR | 71.44 EUR | −9.02% | 0 | 0.00 | 13.42 | 5.32 EUR | +7.88% | 2.38% | Health technology | Neutral |
 VTRSViatris, Inc. | 19.66 B EUR | 17.372 EUR | +1.56% | 0 | 0.00 | — | −0.31 EUR | +87.33% | 2.50% | Health technology | Buy |
 ALNYAlnylam Pharmaceuticals, Inc | 19.22 B EUR | 141.20 EUR | −5.36% | 0 | 0.00 | 8.08 | 17.48 EUR | +8,430.94% | 0.00% | Health technology | Buy |
 IPNIpsen SA | 12.89 B EUR | 154.0 EUR | −2.72% | 0 | 0.00 | 24.92 | 6.18 EUR | +15.12% | 1.03% | Health technology | Neutral |
 RECRecordati S.p.A. | 10.96 B EUR | 53.05 EUR | −0.28% | 0 | — | 22.29 | 2.38 EUR | +22.24% | 2.52% | Health technology | Neutral |
 KRKGKrka, d. d., Novo mesto | 7.73 B EUR | 247.5 EUR | −0.60% | 0 | — | 17.98 | 13.77 EUR | +10.70% | 3.67% | Health technology | Buy |
 ALKBALK-abello A/S Class B | 7.24 B EUR | 32.52 EUR | −1.63% | 0 | — | 39.83 | 0.82 EUR | +35.40% | 0.66% | Health technology | Strong buy |
 LUNAH. Lundbeck A/S Class A | 7.13 B EUR | 6.92 EUR | +1.17% | 0 | 0.00 | 13.26 | 0.52 EUR | +11.06% | 2.27% | Health technology | No rating |
| LUNBH. Lundbeck A/S Class B | 7.13 B EUR | 7.500 EUR | +0.47% | 0 | 0.00 | 14.37 | 0.52 EUR | +11.06% | 2.10% | Health technology | Buy |
 GRFGrifols, S.A. Class A | 6.67 B EUR | 10.995 EUR | −3.00% | 0 | — | 16.54 | 0.66 EUR | +51.93% | 1.68% | Health technology | Buy |
 SFZNSiegfried Holding AG | 3.68 B EUR | 78.50 EUR | −2.91% | 0 | — | 18.53 | 4.24 EUR | +12.47% | 0.53% | Health technology | Buy |
 ROVILaboratorios Farmaceuticos Rovi, S.A. | 3.22 B EUR | 67.65 EUR | −2.87% | 0 | — | 18.68 | 3.62 EUR | +39.34% | 1.22% | Health technology | Buy |
 ALMAlmirall SA | 2.42 B EUR | 11.10 EUR | −1.77% | 0 | — | 40.51 | 0.27 EUR | — | 1.36% | Health technology | Buy |
 DMPDermapharm Holding SE | 1.93 B EUR | 37.85 EUR | −2.70% | 0 | — | 13.72 | 2.76 EUR | +38.58% | 2.26% | Health technology | Buy |
 COPNCosmo N.V. | 1.1 B EUR | 61.5 EUR | −5.53% | 7 | 0.69 | — | −0.38 EUR | −111.41% | 3.22% | Health technology | Strong buy |
 FYBFormycon AG | 330.13 M EUR | 14.08 EUR | −21.69% | 0 | 0.00 | — | −1.42 EUR | +85.20% | 0.00% | Health technology | Strong buy |
 HPHAHeidelberg Pharma AG | 94.04 M EUR | 2.08 EUR | +2.46% | 0 | 0.00 | — | −0.64 EUR | −13.94% | 0.00% | Health technology | Strong buy |
 PTPNPentixapharm Holding AG | 67.66 M EUR | 1.905 EUR | −4.75% | 355 | 975,816,569,651,200.00 | — | — | — | 0.00% | Health technology | Strong buy |